Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management

Annals of Pharmacotherapy

Volumn 36, Issue 2, 2002, Pages 326-330

  Coons, James C ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Fractures; HMG CoA reductase inhibitors; Osteoporosis; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; FRACTURE; HUMAN; MEDICAL LITERATURE; MEDLINE; MORBIDITY; OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR;

EID: 0036164280     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A071     Document Type: Article

References (10)

1. Statins: Lower lipids and better bones?
2. Stimulation of bone formation in vitro and in rodents by statins
3. Do statins prevent both cardiovascular disease and fracture?
4. Statin use, bone mass and fracture: An analysis of two prospective studies
5. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
6. HMG-CoA reductase inhibitors and the risk of fractures
7. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
8. Inhibitors of hyroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
9. Use of statins and risk of fractures